Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

被引：0
|
作者：
Piulats Rodriguez, M. [1 ]
de la Cruz-Merino, L. [2 ]
Espinosa, E. [3 ]
Alonso Carrion, L. [4 ]
Martin Algarra, S. [5 ]
Lopez-Castro, R. [6 ]
Curiel Garcia, M. T. [7 ]
Rodriguez Abreu, D. [8 ]
Rullan Iriarte, A. J. [9 ]
Berrocal Jaime, A. [10 ]
机构：
[1] ICO, Med Oncol, Barcelona, Spain
[2] Hosp Univ Virgen Macarena, Oncol, Seville, Spain
[3] Hosp Univ La Paz, Oncol, Madrid, Spain
[4] Univ Malaga, Oncol, Malaga, Spain
[5] Clin Univ Navarra, Oncol, Navarra, Spain
[6] Hosp Univ Clin Valladolid, Med Oncol, Valladolid, Spain
[7] Hosp Univ Clin Santiago, Oncol, Santiago De Compostela, Spain
[8] Hosp Insular Canarias, Oncol, Las Palmas Gran Canaria, Spain
[9] Inst Catala Oncol, Oncol, Barcelona, Spain
[10] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1247PD
引用
收藏
页码：444 / 444
页数：1
相关论文
共 50 条
  • [1] Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.
    Piulats, Josep M.
    De la Cruz-Merino, Luis
    Garcia, Maria Teresa Curie
    Berrocal, Alfonso
    Alonso-Carrion, Lorenzo
    Espinosa, Enrique
    Castro, Rafael Lopez
    Rodriguez-Abreu, Delvys
    Fra, Pablo Luna
    Martin-Algarra, Salvador
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
    Maria Piulats, Jose
    Espinosa, Enrique
    de la Cruz-Merino, Luis
    Varela, Mar
    Alonso Carrion, Lorenzo
    Martin-Algarra, Salvador
    Lopez Castro, Rafael
    Curiel, Teresa
    Rodriguez-Abreu, Delvys
    Redrado, Miriam
    Goma, Montserrat
    Jose Rullan, Antonio
    Calvo Gonzalez, Alfonso
    Berrocal-Jaime, Alfonso
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 586 - +
  • [3] Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study
    Pelster, Meredith S.
    Gruschkus, Stephen K.
    Bassett, Roland
    Gombos, Dan S.
    Shephard, Michael
    Posada, Liberty
    Glover, Maura S.
    Simien, Rinata
    Diab, Adi
    Hwu, Patrick
    Carter, Brett W.
    Patel, Sapna P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 599 - +
  • [4] Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institutional retrospective study
    Namikawa, K.
    Takahashi, A.
    Tsutsumida, A.
    Mori, T.
    Motoi, N.
    Jinnai, S.
    Kage, Y.
    Muto, Y.
    Nakano, E.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28 : 114 - 114
  • [5] Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study
    Namikawa, Kenjiro
    Takahashi, Akira
    Mori, Taisuke
    Tsutsumida, Arata
    Suzuki, Shigenobu
    Motoi, Noriko
    Jinnai, Shunichi
    Kage, Yuta
    Mizuta, Haruki
    Muto, Yusuke
    Nakano, Eiji
    Yamazaki, Naoya
    MELANOMA RESEARCH, 2020, 30 (01) : 76 - 84
  • [6] Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
    Najjar, Yana G.
    Navrazhina, Kristina
    Ding, Fei
    Bhatia, Roma
    Tsai, Katy
    Abbate, Kelly
    Durden, Barbara
    Eroglu, Zeynep
    Bhatia, Shailender
    Park, Song
    Chowdhary, Akansha
    Chandra, Sunandana
    Kennedy, Jonathan
    Ernstoff, Marc
    Vachhani, Pankit
    Drabick, Joseph
    Singh, Arun
    Xu, Tan
    Yang, Jessica
    Carvajal, Richard
    Manson, Daniel
    Kirkwood, John
    Cohen, Justine
    Sullivan, Ryan
    Johnson, Douglas
    Funchain, Pauline
    Shoushtari, Alexander
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [7] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [8] Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02
    Rullan Iriarte, A. J.
    Martin-Algarra, S.
    de la Cruz-Merino, Luis
    Rodriguez Abreu, D.
    Espinosa, E.
    Berrocal, A.
    Lopez Castro, R.
    Curiel, T.
    Luna, P.
    Lorenzo, A.
    Piulats, J. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Thomas K. Eigentler
    Felix Kiecker
    Jan Simon
    Jochen Utikal
    Peter Mohr
    Carola Berking
    Eckhart Kämpgen
    Edgar Dippel
    Rudolf Stadler
    Axel Hauschild
    Michael Fluck
    Patrick Terheyden
    Rainer Rompel
    Carmen Loquai
    Zeinab Assi
    Claus Garbe
    Dirk Schadendorf
    Journal of Translational Medicine, 13
  • [10] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Zimmer, Lisa
    Eigentler, Thomas K.
    Kiecker, Felix
    Simon, Jan
    Utikal, Jochen
    Mohr, Peter
    Berking, Carola
    Kaempgen, Eckhart
    Dippel, Edgar
    Stadler, Rudolf
    Hauschild, Axel
    Fluck, Michael
    Terheyden, Patrick
    Rompel, Rainer
    Loquai, Carmen
    Assi, Zeinab
    Garbe, Claus
    Schadendorf, Dirk
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
12345